Pneumonitis as a side effect of breast cancer treatment: T-DXd and/or SBRT?

Pneumonitis as a side effect of breast cancer treatment: T-DXd and/or SBRT?

Breast cancer that overexpresses the human epidermal growth factor receptor 2 (HER2) is considered to be HER2-positive. The novel HER2- directed antibody drug conjugate, trastuzumab deruxtecan (T-DXd), is formed by covalently joining the monoclonal antibody trastuzumab with the topoisomerase I inhi...

Full description

Bibliographic Details
Main Authors: Džana Bjelić, Sara Bognar, Jelena Benčić, Manuela Bajan, Natalija Dedić Plavetić
Format: Article
Language:English
Published: Hrvatski liječnički zbor 2023-01-01
Series:Liječnički vjesnik
Subjects:
breast cancer
metastasis
pneumonitis
trastuzumab deruxtecan
Online Access:https://hrcak.srce.hr/file/438256

Similar Items

Similar Items